Aspire Biopharma
ASBP
2 hedge funds and large institutions have $150K invested in Aspire Biopharma in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 0 reducing their positions, and 2 closing their positions.
65% more capital invested
Capital invested by funds: $90.4K → $150K (+$59.2K)
0% less ownership
Funds ownership: 0% → 0% (-0%)
33% less funds holding
Funds holding: 3 → 2 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
Robinson Capital Management
Grosse Pointe Farms,
Michigan
|
+$54.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$8.75K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CS
1
Clear Street
New York
| $93.9K | – | – | – |
|
|
RCM
2
Robinson Capital Management
Grosse Pointe Farms,
Michigan
| $55.7K | +$54.4K | +4 | New |
|
|
3
UBS Group
Zurich,
Switzerland
| – | -$8.75K | -1 | Closed |
|
ASBP Hedge Fund Activity: Q3 2024 in Review
2 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma (ASBP) for Q3 2024, worth a combined $150K — up 65% from $90.4K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ASBP and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest buyer was Robinson Capital Management, opening a new position worth an estimated $54.4K. The largest seller was UBS Group, exiting entirely with an estimated $8.75K sold.
- 2 institutional investors held Aspire Biopharma (ASBP) as of Q3 2024, down from 3 in Q2 2024.
- Funds reported $150K of Aspire Biopharma stock for Q3 2024, up 65% quarter-over-quarter.
- 1 fund opened new Aspire Biopharma positions in Q3 2024 and 2 closed out, a net change of -1 holder.
- The largest Aspire Biopharma buyer in Q3 2024 was Robinson Capital Management, an estimated $54.4K added.
- The largest Aspire Biopharma seller in Q3 2024 was UBS Group, an estimated $8.75K sold.
Based on aggregated 13F filings for Q3 2024.